Login to Your Account

IND nod comes just in 'Tyme' for phase II study of breast cancer drug

By Marie Powers
News Editor

Tuesday, October 27, 2015
FDA acceptance of the investigational new drug (IND) application for SM-88, a metabolic inhibitor that targets cancer cells, gave the green light to developer Tyme Inc., through wholly owned subsidiary Tyme Technologies Inc., to begin enrolling patients in a multicenter phase II study targeting breast cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription